Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC) | UCSF Helen Diller Family Comprehensive Cancer Center

Author List

Aggarwal, R.R., Vuky, J., VanderWeele, D.J., Rettig, M., Heath, E.I., Beer, T.M., Huang, J., Pawlowska, N., Sinit, R., Abbey, J., Liu, B., Nasoff, M., Dorr, A., Small, E.J.

Publication

Journal of Clinical Oncology

Publication ID (Profile URL)

https://researcherprofiles.org/profile/530203619

Publication Year

2022

Publication Title

Aggarwal, R.R., Vuky, J., VanderWeele, D.J., Rettig, M., Heath, E.I., Beer, T.M., Huang, J., Pawlowska, N., Sinit, R., Abbey, J., Liu, B., Nasoff, M., Dorr, A., Small, E.J. . Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2022; 16(40):s3001.